Overview
$222.5M Revenue, fiscal 20212 $1.0M Net income, fiscal 20212 Industry Pharmaceutical Preparations Headquarters X0 Incorporated in United Kingdom3 Business address Dept 920A, 196 High Road, Wood Green, London, X0 N22 8Hh3 Filer category Accelerated filer, Emerging growth company3 See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2021 21.9% Revenue growth, 20212 Where the money goes Where each dollar of revenue went, fiscal 2021 Other costs
Other costs 100¢ $221.5M Profit 0¢ $1.0M Out of $222.5M in revenue.2
Where each dollar of operating cash went, fiscal 2021 Kept or used elsewhere
Capital spending 5¢ $729.0K Kept or used elsewhere 95¢ $14.8M Out of $15.5M of cash from operations.2
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 2 $222.5M in 2021+1202% since 2018 0 $100.0M $200.0M $300.0M 2018: $17.1M $17.1M 2018 2019: $58.1M $58.1M 2019 +240% 2020: $182.6M $182.6M 2020 +214% 2021: $222.5M $222.5M 2021 +22% Gross profit4 2 $116.4M in 2021+975% since 2018 0 $50.0M $100.0M $150.0M 2018: $10.8M $10.8M 2018 2019: $19.4M $19.4M 2019 +79% 2020: $63.6M $63.6M 2020 +228% 2021: $116.4M $116.4M 2021 +83% Operating income4 2 -$38.6M in 2021+114% since 2018 -$60.0M -$40.0M -$20.0M 0 2018: -$18.0M -$18.0M 2018 2019: -$50.5M -$50.5M 2019 +180% 2020: -$46.5M -$46.5M 2020 −8% 2021: -$38.6M -$38.6M 2021 −17% Net income4 2 $1.0M in 2021-$150.0M -$100.0M -$50.0M 0 $50.0M 2018: -$30.5M -$30.5M 2018 2019: -$63.0M -$63.0M 2019 +107% 2020: -$104.5M -$104.5M 2020 +66% 2021: $1.0M $1.0M 2021 No quarterly figures reported.
Fiscal year 2017 2018 2019 2020 2021 Revenue $17.1M4 $58.1M2 $182.6M2 $222.5M2 Gross profit $10.8M4 $19.4M2 $63.6M2 $116.4M2 Operating income -$18.0M4 -$50.5M2 -$46.5M2 -$38.6M2 Net income -$30.5M4 -$63.0M2 -$104.5M2 $1.0M2 Earnings per share -$0.832 -$0.662 $0.002 Earnings per share (diluted) -$0.832 -$0.662 $0.002
Total assets4 2 $816.1M in 2021+55% since 2019 0 $250.0M $500.0M $750.0M $1.0B 2019: $527.1M $527.1M 2019 2020: $536.6M $536.6M 2020 +2% 2021: $816.1M $816.1M 2021 +52% Total liabilities4 2 $459.4M in 2021+16% since 2019 0 $200.0M $400.0M $600.0M 2019: $395.3M $395.3M 2019 2020: $470.4M $470.4M 2020 +19% 2021: $459.4M $459.4M 2021 −2% Shareholders’ equity4 2 $356.7M in 2021+1269% since 2017 -$100.0M 0 $100.0M $200.0M $300.0M $400.0M 2017: $26.0M $26.0M 2017 2018: -$3.7M -$3.7M 2018 2019: $131.8M $131.8M 2019 2020: $66.1M $66.1M 2020 −50% 2021: $356.7M $356.7M 2021 +439% Cash4 2 $113.0M in 2021+363% since 2017 0 $50.0M $100.0M $150.0M 2017: $24.4M $24.4M 2017 2018: $11.2M $11.2M 2018 −54% 2019: $67.2M $67.2M 2019 +499% 2020: $118.8M $118.8M 2020 +77% 2021: $113.0M $113.0M 2021 −5% No quarterly figures reported.
Fiscal year 2017 2018 2019 2020 2021 Cash $24.4M4 $11.2M2 $67.2M2 $118.8M2 $113.0M2 Total assets $527.1M4 $536.6M2 $816.1M2 Total liabilities $395.3M4 $470.4M2 $459.4M2 Shareholders’ equity $26.0M4 -$3.7M2 $131.8M2 $66.1M2 $356.7M2 Shares outstanding 178.8M shares4 319.8M shares2
Cash from operations4 2 $15.5M in 2021-$40.0M -$20.0M 0 $20.0M $40.0M 2018: -$15.5M -$15.5M 2018 2019: -$37.5M -$37.5M 2019 +142% 2020: $26.9M $26.9M 2020 2021: $15.5M $15.5M 2021 −42% Capital spending4 2 $729.0K in 2021+811% since 2018 0 $500.0K $1.0M $1.5M $2.0M 2018: $80.0K $80.0K 2018 2019: $578.0K $578.0K 2019 +622% 2020: $1.5M $1.5M 2020 +160% 2021: $729.0K $729.0K 2021 −51% Free cash flow4 2 $14.8M in 2021-$40.0M -$20.0M 0 $20.0M $40.0M 2018: -$15.5M -$15.5M 2018 2019: -$38.0M -$38.0M 2019 +145% 2020: $25.4M $25.4M 2020 2021: $14.8M $14.8M 2021 −42% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2017 2018 2019 2020 2021 Cash from operations -$15.5M4 -$37.5M2 $26.9M2 $15.5M2 Capital spending $80.0K4 $578.0K2 $1.5M2 $729.0K2 Free cash flow -$15.5M -$38.0M $25.4M $14.8M
Compare Amryt Pharma plc with another company
Former names
Amryt Pharma Holdings Ltd Aug 8, 2019 to Aug 8, 20193
Recent filings
Apr 12, 2023 6-K Apr 3, 2023 6-K Mar 23, 2023 6-K Feb 16, 2023 6-K Jan 9, 2023 6-K Jan 3, 2023 6-K Nov 3, 2022 6-K Aug 4, 2022 6-K Jul 1, 2022 6-K Jun 24, 2022 6-K Jun 23, 2022 6-K Jun 9, 2022 6-K Jun 1, 2022 6-K May 11, 2022 6-K May 4, 2022 6-K Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
